Chondroitin sulfate proteoglycan analogue microspheres and preparation method thereof

By chondroitin sulfate proteoglycan analog microspheres that simulate natural proteoglycan structure, the problem of material in injectable in spinal cord injury is solved, providing a spinal cord regeneration environment and reducing drug side effects, achieving the accuracy and stability of drug release sex.

CN118994601AActive Publication Date: 2024-11-22JIANGNAN UNIV

Patent Information

Application Number
CN202411099022.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-22
Estimated Expiration
2044-08-12

AI Technical Summary

Technical Problem

It is difficult to effectively study and apply the structure-activity mechanism of chondroitin sulfate proteoglycan in spinal cord injury, and traditional spinal cord tissue engineering materials cannot be injected, resulting in difficult treatment.

Method used

Using methacrylylated gelatin as the core protein backbone, simulate the structure of natural proteoglycans through amidation reaction, prepare chondroitin sulfate proteoglycan analog microspheres with controllable size and subtypes, and through microfluidic devices, Cross-linking under ultraviolet light forms injectable hydrogel microspheres for minimally invasive treatment of spinal cord injury.

Benefits of technology

The controllability and stability of the chondroitin sulfate proteoglycan analog is achieved, providing a spinal cord regeneration environment, reducing systemic drug side effects, and improving the accuracy and stability of drug release.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994601A_ABST
    Figure CN118994601A_ABST
Patent Text Reader

Abstract

The invention relates to chondroitin sulfate proteoglycan analogue microspheres and a preparation method thereof, and belongs to the technical field of biological medicines. The preparation method comprises the following steps: S1, carrying out enzymolysis on chondroitin sulfate by adopting chondroitin sulfatase to obtain chondroitin sulfate oligosaccharide; s2, the activated chondroitin sulfate oligosaccharide and methacrylated gelatin with a low grafting rate are subjected to a coupling reaction, and a chondroitin sulfate proteoglycan analogue is obtained; s3, dissolving a chondroitin sulfate proteoglycan analogue, methacrylated gelatin with a high grafting rate and a photoinitiator in water to obtain a dispersion phase; the oil phase material is a continuous phase; and S4, preparing the dispersed phase and the continuous phase into water-in-oil type liquid drops through a microfluidic device, and carrying out ultraviolet curing and washing to obtain the microspheres. The microsphere provided by the invention can regulate and control the microenvironment of a lesion part after spinal cord injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a chondroitin sulfate proteoglycan analog microsphere and a preparation method thereof. Background Art

[0002] The spinal cord is the place where the human body's nerves gather most densely, and is responsible for transmitting nerve signals between the brain and various parts of the body. When the spinal cord is injured, the nerves may be compressed to varying degrees or even broken, resulting in loss of nerve function. This complex physiological structure makes the treatment of spinal cord injury particularly difficult. Spinal cord injury, as a serious disabling injury, often causes varying degrees of paraplegia or quadriplegia. The somatic dysfunction and autonomic dysfunction caused by it have seriously affected the patient's ability to take care of themselves and participate in social activities. Due to the characteristics of nerve cells that cannot regenerate, improving the microenvironment of the injured area is the key to accelerating axon regeneration and synapse formation. Therefore, tissue engineering is an effective means to improve the microenvironment of the spinal cord lesion area.

[0003] Different from other tissues, the central nervous system is specifically rich in chondroitin sulfate proteoglycans (CSPGs). This type of proteoglycan has a highly similar core protein structure. Glycosaminoglycan side chains of different structures and densities are connected to the core protein peptide chain through serine residues, and the content and distribution show significant spatiotemporal specificity. Under normal physiological conditions, CSPGs are wrapped around the proximal ends of somatic cells or certain neuronal dendrites in the form of neural grids, participating in stabilizing existing synapses, inhibiting the morphology of abnormally linked synapses, and regulating the interaction between cells and the extracellular matrix. Under pathological conditions, glial scars are formed at the site of injury, and their CSPG content increases rapidly, inhibiting nerve repair.

[0004] However, due to the complexity of CSPG structure and the difficulty of obtaining it, it is difficult to conduct in-depth research on the structure-activity mechanism of proteoglycans and nerve regeneration. At present, proteoglycans are mainly mixtures extracted from animal connective tissue, which makes quality control difficult, and there is a risk of viral contamination in biological products. There are no related commercial products. There are also few reports on the research of artificially synthesized proteoglycans. At the same time, spinal cord tissue engineering usually uses collagen, hyaluronic acid and other materials as hydrogel matrices. Due to their non-injectability, cutting the vertebrae will cause greater trauma. Therefore, it is necessary to use artificially synthesized proteoglycan analogs to further study their structure-activity mechanism in various physiological and pathological conditions. Summary of the invention

[0005] To solve the above technical problems, the present invention provides a chondroitin sulfate proteoglycan analog microsphere and a preparation method thereof, which simulates the comb-shaped chain structure and sugar chain structure of natural proteoglycan, uses methacrylylated gelatin as the core protein skeleton, and grafts sugar chains of different sizes and subtypes onto its surface through an amidation reaction, thereby realizing a chondroitin sulfate proteoglycan analog with controllable sugar chain subtype and controllable size. At the same time, in order to avoid the secondary trauma caused by cutting the vertebrae for direct implantation, it is cross-linked under ultraviolet light through a microfluidic device to make an injectable size hydrogel microsphere, which can meet the needs of minimally invasive treatment. In addition, the microsphere can also adsorb growth factors in the supernatant of stem cells and encapsulate nanoparticles such as liposomes and release drugs slowly and controlled, thereby providing a new strategy for the combined treatment of spinal cord injury. The sustained-release methylprednisolone replaces the acute phase methylprednisolone shock therapy to reduce the side effects of systemic administration. The successful encapsulation of liposomes can improve the stability of liposomes, and has the application prospect of graded release of different drugs. The surface area and volume ratio of the hydrogel is improved, the contact area between cells and materials is increased, and it is more suitable to provide growth space for spinal cord regeneration.

[0006] The first object of the present invention is to provide a method for preparing chondroitin sulfate proteoglycan analog microspheres, comprising the following steps:

[0007] S1, enzymatically hydrolyzing chondroitin sulfate with chondroitinase, and obtaining chondroitin sulfate oligosaccharides by ultrafiltration;

[0008] S2, activating the chondroitin sulfate oligosaccharide described in S1 by a cross-linking agent, and then coupling reaction with the first methacryloyl gelatin, dialyzing and freeze-drying to obtain chondroitin sulfate proteoglycan analog (GMCS); the double bond grafting rate of the first methacryloyl gelatin (GelMA (L)) is 30%-40%, which is conducive to the covalent cross-linking of the remaining amino groups on the gelatin with chondroitin sulfate;

[0009] S3, dissolving the chondroitin sulfate proteoglycan analogue described in S2, the second methacryloyl gelatin and the photoinitiator in water to obtain a dispersed phase; the double bond grafting rate of the second methacryloyl gelatin (GelMA (H)) is 70%-80%, and the mechanical properties of the microspheres are stronger after photocrosslinking;

[0010] The oil phase material is the continuous phase;

[0011] S4. The dispersed phase and the continuous phase described in S3 are made into water-in-oil droplets through a microfluidic device, and the chondroitin sulfate proteoglycan analog microspheres are obtained through UV curing and washing.

[0012] In one embodiment of the present invention, in S1, the chondroitinase is selected from chondroitin sulfate ABC enzyme (ChABC) or chondroitin sulfate AC enzyme (ChAC);

[0013] And / or, the chondroitin sulfate is selected from one or more of chondroitin sulfate A (CSA), chondroitin sulfate C (CSC) and chondroitin sulfate E (CSE).

[0014] In one embodiment of the present invention, in S1, the conditions of the enzymatic hydrolysis are: temperature of 20°C-37°C, time of 20h-30h;

[0015] And / or, during the enzymatic hydrolysis process, the concentration of chondroitinase is 0.2 mg / mL-0.5 mg / mL, and the concentration of chondroitin sulfate is 1 mg / mL-5 mg / mL.

[0016] In one embodiment of the present invention, in S1, chondroitin sulfate oligosaccharides of different molecular weights can be obtained by ultrafiltration.

[0017] In one embodiment of the present invention, in S2, the cross-linking agent includes EDC and NHS; the mass ratio of EDC to NHS is 1:(1-3);

[0018] And / or, the mass ratio of the chondroitin sulfate oligosaccharide, the first methacryloyl gelatin and the cross-linking agent is (40-60):250:(6-11).

[0019] In one embodiment of the present invention, in S3, the photoinitiator is selected from photoinitiator LAP;

[0020] And / or, the oil phase material is selected from one or more of Span 80, Span 60, paraffin oil, castor oil and soybean oil.

[0021] In one embodiment of the present invention, in S3, the mass ratio of the chondroitin sulfate proteoglycan analog to the second methacryloyl gelatin is 1:(2-4); the mass ratio of the second methacryloyl gelatin to the photoinitiator is (10-40):1.

[0022] In one embodiment of the present invention, in S4, the specifications of the microfluidic device are: channel depth is 30μm-60μm, constriction width is 60μm-120μm, inner diameter of the pipeline is 0.3mm-0.6mm, and outer diameter of the pipeline is 1mm-2mm.

[0023] In one embodiment of the present invention, in S4, the microfluidic device uses a dual-channel injection pump, the chip uses a T-channel microfluidic chip, and the pipeline uses a tygon hose.

[0024] In one embodiment of the present invention, in S4, the process parameters of the microfluidic device are: the flow rate of the dispersed phase is 0.3 mL / h-0.8 mL / h, and the flow rate of the continuous phase is 5 mL / h-10 mL / h.

[0025] In one embodiment of the present invention, in S4, the UV curing conditions are: wavelength of 365nm-405nm, irradiation power of 50mW·cm -2 -200mW·cm -2 The irradiation time is 30s-180s.

[0026] And / or, the washing is firstly with petroleum ether and then with water.

[0027] The second object of the present invention is to provide a chondroitin sulfate proteoglycan analog microsphere prepared by the method described above, wherein the diameter of the chondroitin sulfate proteoglycan analog microsphere is 50 μm-200 μm.

[0028] The technical solution of the present invention has the following advantages over the prior art:

[0029] (1) The chondroitin sulfate proteoglycan analogs described in the present invention are covalently linked via amide bonds, and their size and subtype are controllable, providing a technical solution for regulating the microenvironment after spinal cord injury and for in-depth research on the structure-activity mechanism of chondroitin sulfate proteoglycans of different subtypes and molecular weights in various physiological and pathological conditions.

[0030] (2) The chondroitin sulfate proteoglycan analogs described in the present invention are photo-crosslinkable, which expands their functions and applications and has good application prospects in the biomedical field.

[0031] (3) The diameter of the chondroitin sulfate proteoglycan analog microspheres of the present invention is 50 μm-200 μm, and they have good stability and swelling properties. At the same time, the pore structure of the microspheres allows nano-scale liposomes to be embedded therein, and the stability of the microspheres can protect the liposomes from being damaged during transportation and release, giving the liposomes certain controlled release properties, which helps to achieve directional delivery and precise release of the liposomes.

[0032] (4) The chondroitin sulfate proteoglycan analog microspheres of the present invention can absorb growth factors through electrostatic interaction due to their negative charge, simulating the extracellular matrix composition of the human spinal cord and regulating the microenvironment of the lesion after spinal cord injury. This lays a technical foundation for subsequent research on the mechanism of action of different subtypes of chondroitin sulfate proteoglycans on nerve repair.

[0033] (5) The chondroitin sulfate proteoglycan analog microspheres prepared by the preparation method of the present invention are uniform in size, so that methylprednisolone is evenly distributed in the chondroitin sulfate proteoglycan microspheres, thereby being continuously released at the site of spinal cord injury, reducing the nonspecific distribution of the drug in the body, reducing the fluctuation of blood drug concentration, and thus reducing its toxic side effects on the lungs and gastrointestinal tract. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein:

[0035] Figure 1 is the ultraviolet absorption graph of chondroitin sulfate A oligosaccharide in Test Example 1 of the present invention;

[0036] Figure 2 The H-NMR spectra of GelMA (L) and GMCS in Test Example 2 of the present invention;

[0037] Figure 3 The nuclear magnetic hydrogen spectra of chondroitin sulfate A oligosaccharide and GMCS in Test Example 2 of the present invention;

[0038] Figure 4 The contact angle diagrams of GelMA (L) and GMCS in Test Example 5 of the present invention; wherein the left diagram is GelMA (L) and the right diagram is GMCS;

[0039] Figure 5 The swelling results of GelMA (H) microspheres and GMCS microspheres in Test Example 6 of the present invention are shown in the figure; the upper figure is a microscope image of GelMA (H) microspheres, the middle figure is a microscope image of GMCS microspheres, and the lower figure is the change in the diameter of the microspheres after analysis by image J software;

[0040] Figure 6 This is the release curve of the drug methylprednisolone by the drug GMCS microspheres in Test Example 7 of the present invention;

[0041] Figure 7 Characterization diagrams of GelMA (H) microspheres, GMCS microspheres, and liposome-encapsulated GMCS microspheres in Test Example 8 of the present invention; wherein the upper diagram is a SEM diagram of GelMA (H) microspheres, the middle diagram is a SEM diagram of GMCS microspheres, and the lower diagram is a SEM diagram of liposome-encapsulated GMCS microspheres;

[0042] Figure 8 This is an SDS-PAGE image of the growth factors in the supernatant of stem cells adsorbed by GMCS microspheres in Test Example 9 of the present invention;

[0043] Fig. 9 The changes in the storage modulus (G') and loss modulus (G") of the chondroitin sulfate proteoglycan analog GMCS microspheres in Test Example 10 of the present invention. DETAILED DESCRIPTION

[0044] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. It should be understood that the specific embodiments are only used to explain the present invention, but the embodiments are not intended to limit the present invention.

[0045] In the present invention, unless otherwise explained, technical and scientific terms used in the present invention have the same meanings as commonly understood by those skilled in the art to which the present invention belongs.

[0046] In the present invention, unless otherwise stated, the term "and / or" used in the present invention includes any and all combinations of one or more of the associated listed items.

[0047] In the present invention, unless otherwise stated, the experimental methods used in the embodiments of the present invention are conventional methods unless otherwise stated, and the materials, reagents, etc. used are all commercially available unless otherwise stated.

[0048] In the present invention, unless otherwise specified, the microfluidic device used in the embodiments of the present invention uses a dual-channel injection pump, the chip uses a T-channel microfluidic chip, and the pipeline uses a tygon hose; the specifications of the microfluidic device are: the channel depth is 50μm, the neck width is 100μm, the inner diameter of the pipeline is 0.51mm, and the outer diameter of the pipeline is 1.52mm.

[0049] In the present invention, unless otherwise specified, the preparation of the liposome solution used in the embodiments of the present invention comprises the following steps: 60 mg of lecithin and 15 mg of cholesterol are weighed and dissolved in 30 mL of chloroform at 50° C., poured into an eggplant-shaped bottle and subjected to rotary evaporation from slow to fast speed in a 50° C. water bath to form a phospholipid membrane, which is vacuum dried for 12 h and then incubated with a phosphate buffer solution at 50° C. for 30 min to form a liposome solution, and after ultrasonication in an ice bath, the liposome solution is passed through a 0.45 μm and 0.22 μm membrane for 3 times and placed at 4° C. until the next use.

[0050] Example 1

[0051] The chondroitin sulfate proteoglycan analog microspheres and the preparation method thereof of this embodiment specifically include the following steps:

[0052] S1. Preparation of chondroitin sulfate oligosaccharides: 10 mg of chondroitin sulfate A was dissolved in 50 mM Tris / 60 mM sodium acetate (pH = 8.0) in an enzymatic hydrolysis buffer, 110 μL of 1 mg / mL ChABC was added, and the mixture was placed on a shaker at 37°C and 100 rpm for 24 h. After the shaking, the mixture was boiled and filtered to remove the protein. The mixture was then passed through 10 kDa, 5 kDa, 3 kDa, and 1 kDa ultrafiltration centrifuge tubes in sequence, and centrifuged at 4°C and 4000 rpm for 50 min to obtain 1 kDa-3 kDa, 3 kDa-5 kDa, and 5 kDa-10 kDa chondroitin sulfate A oligosaccharides.

[0053] S2. Preparation of methacryloyl gelatin: Two portions of 10 g of type A gelatin were heated in a water bath at 50°C for 1 h to dissolve, and then 15 mL and 2 mL of methyl methacrylate (MA) were slowly added dropwise respectively, and the mixture was reacted at 50°C in the dark for 24 h. The mixture was dialyzed using a 3500 Da dialysis bag at 37°C in the dark for five days, and then freeze-dried to obtain methacryloyl gelatin GelMA (H) with a high double bond grafting rate and methacryloyl gelatin GelMA (L) with a low double bond grafting rate, respectively.

[0054] S3. Preparation of chondroitin sulfate proteoglycan analogs: 50 mg of chondroitin sulfate A oligosaccharide was dissolved in 10 mL of MES (pH = 5.5), 3 mg of EDC and 4 mg of NHS were added for activation for 1 h, and then mixed with 250 mg of GelMA (L) dissolved in 125 mL of PBS (pH = 7.4) and reacted in the dark for 24 h to obtain a coupling product, and finally dialyzed and freeze-dried to obtain chondroitin sulfate proteoglycan analog GMCS;

[0055] S4. Preparation of microspheres: 100 mg of GelMA (H) and 5 mg of photoinitiator LAP were mixed in 1 mL of deionized water to obtain a first pregel solution; 40 mg of chondroitin sulfate proteoglycan analog GMCS, 100 mg of GelMA (H) and 5 mg of photoinitiator LAP were mixed in 1 mL of deionized water to obtain a second pregel solution; the two pregel solutions were used as dispersed phases respectively; 2.5 mL of Span 80 was added to 50 mL of paraffin oil as a continuous phase; the dispersed phase (flow rate of 0.5 mL / h) and the continuous phase (flow rate of 8 mL / h) were made into oil-in-water droplets by a microfluidic device, and exposed to 405 nm, 100 mW·cm in the subsequent pipeline. -2 Two kinds of hydrogel microspheres were formed under ultraviolet light for 1 min, and then washed with petroleum ether and water for 4 times in sequence, and dried to obtain chondroitin sulfate proteoglycan analog GMCS microspheres.

[0056] Example 2

[0057] The chondroitin sulfate proteoglycan analog microspheres and the preparation method thereof of this embodiment specifically include the following steps:

[0058] S1. Preparation of chondroitin sulfate oligosaccharides: 10 mg of chondroitin sulfate A was dissolved in 50 mM Tris / 60 mM sodium acetate (pH = 8.0) in an enzymatic hydrolysis buffer, 110 μL of 1 mg / mL ChABC was added, and the mixture was placed on a shaker at 37°C and 100 rpm for 24 h. After the shaking, the mixture was boiled and filtered to remove the protein. The mixture was then passed through 10 kDa, 5 kDa, 3 kDa, and 1 kDa ultrafiltration centrifuge tubes in sequence, and centrifuged at 4°C and 4000 rpm for 50 min to obtain 1 kDa-3 kDa, 3 kDa-5 kDa, and 5 kDa-10 kDa chondroitin sulfate A oligosaccharides.

[0059] S2. Preparation of methacryloyl gelatin: Two portions of 10 g of type A gelatin were heated in a water bath at 50°C for 1 h to dissolve, and then 15 mL and 2 mL of methyl methacrylate (MA) were slowly added dropwise respectively, and the mixture was reacted at 50°C in the dark for 24 h. The mixture was dialyzed using a 3500 Da dialysis bag at 37°C in the dark for five days, and then freeze-dried to obtain methacryloyl gelatin GelMA (H) with a high double bond grafting rate and methacryloyl gelatin GelMA (L) with a low double bond grafting rate, respectively.

[0060] S3. Preparation of chondroitin sulfate proteoglycan analogs: 50 mg of chondroitin sulfate A oligosaccharide was dissolved in 10 mL of MES (pH = 5.5), 3 mg of EDC and 4 mg of NHS were added for activation for 1 h, and then mixed with 250 mg of GelMA (L) dissolved in 125 mL of PBS (pH = 7.4) and reacted in the dark for 24 h to obtain a coupling product, and finally dialyzed and freeze-dried to obtain chondroitin sulfate proteoglycan analog GMCS;

[0061] S4. Preparation of microspheres: 40 mg of GMCS, 100 mg of GelMA (H), 40 mg of MPSS, and 5 mg of LAP were mixed in 1 mL of deionized water to obtain a pre-gel solution as the dispersed phase; 2.5 mL of Span 80 was added to 50 mL of paraffin oil as the continuous phase; the dispersed phase (flow rate of 0.5 mL / h) and the continuous phase (flow rate of 8 mL / h) were made into water-in-oil droplets by a microfluidic device, and exposed to 405 nm, 100 mW·cm in the subsequent pipeline. -2 The hydrogel microspheres were formed under ultraviolet light for 1 min, and then washed 4 times with petroleum ether and water in sequence, and dried to obtain the drug chondroitin sulfate proteoglycan analog GMCS microspheres.

[0062] Example 3

[0063] The chondroitin sulfate proteoglycan analog microspheres and the preparation method thereof of this embodiment specifically include the following steps:

[0064] S1. Preparation of chondroitin sulfate oligosaccharides: 10 mg of chondroitin sulfate A was dissolved in 50 mM Tris / 60 mM sodium acetate (pH = 8.0) in an enzymatic hydrolysis buffer, 110 μL of 1 mg / mL ChABC was added, and the mixture was placed on a shaker at 37°C and 100 rpm for 24 h. After the shaking, the mixture was boiled and filtered to remove the protein. The mixture was then passed through 10 kDa, 5 kDa, 3 kDa, and 1 kDa ultrafiltration centrifuge tubes in sequence, and centrifuged at 4°C and 4000 rpm for 50 min to obtain 1 kDa-3 kDa, 3 kDa-5 kDa, and 5 kDa-10 kDa chondroitin sulfate A oligosaccharides.

[0065] S2. Preparation of methacryloyl gelatin: Two portions of 10 g of type A gelatin were heated in a water bath at 50°C for 1 h to dissolve, and then 15 mL and 2 mL of methyl methacrylate (MA) were slowly added dropwise respectively, and the mixture was reacted at 50°C in the dark for 24 h. The mixture was dialyzed using a 3500 Da dialysis bag at 37°C in the dark for five days, and then freeze-dried to obtain methacryloyl gelatin GelMA (H) with a high double bond grafting rate and methacryloyl gelatin GelMA (L) with a low double bond grafting rate, respectively.

[0066] S3. Preparation of chondroitin sulfate proteoglycan analogs: 50 mg of chondroitin sulfate A oligosaccharide was dissolved in 10 mL of MES (pH = 5.5), 3 mg of EDC and 4 mg of NHS were added for activation for 1 h, and then mixed with 250 mg of GelMA (L) dissolved in 125 mL of PBS (pH = 7.4) and reacted in the dark for 24 h to obtain a coupling product, and finally dialyzed and freeze-dried to obtain chondroitin sulfate proteoglycan analog GMCS;

[0067] S4. Preparation of microspheres: 40 mg of GMCS, 100 mg of GelMA (H), 5 mg of LAP, and 200 μL of liposome solution were mixed in 1 mL of deionized water to obtain a pre-gel solution as the dispersed phase; 2.5 mL of Span 80 was added to 50 mL of paraffin oil as the continuous phase; the dispersed phase (flow rate of 0.5 mL / h) and the continuous phase (flow rate of 8 mL / h) were made into oil-in-water droplets by a microfluidic device, and exposed to 405 nm, 100 mW·cm in the subsequent pipeline. -2 The hydrogel microspheres were formed under ultraviolet light for 1 min, and then washed with petroleum ether and water for 4 times, and dried to obtain liposome-encapsulated chondroitin sulfate proteoglycan analog GMCS microspheres.

[0068] Comparative Example 1 is basically the same as Example 1, except that in S3, the amount of GelMA (L) used is 150 mg (the mass ratio of chondroitin sulfate A oligosaccharide to GelMA (L) is 1:3).

[0069] Comparative Example 2 is basically the same as Example 1, except that in S3, the amount of GelMA (L) used is 350 mg (the mass ratio of chondroitin sulfate A oligosaccharide to GelMA (L) is 1:7).

[0070] Comparative Example 3 is basically the same as Example 1, except that in S4, the amount of GMCS, a chondroitin sulfate proteoglycan analog, is 20 mg (the mass ratio of GMCS to GelMA (H) is 1:5).

[0071] Comparative Example 4 is basically the same as Example 1, except that in S4, the amount of GMCS, a chondroitin sulfate proteoglycan analog, is 60 mg (the mass ratio of GMCS to GelMA (H) is 3:5).

[0072] Test Example 1

[0073] The chondroitin sulfate A oligosaccharide of Example 1 was subjected to UV analysis at a wavelength range of 200-500 nm. The results are as follows: Figure 1 As shown. Figure 1 It can be seen that chondroitin sulfate A oligosaccharide has obvious ultraviolet absorption at 232nm, which is the characteristic absorption peak of unsaturated double bonds produced at the non-reducing end of the sugar chain when chondroitin sulfate restriction endonuclease degrades chondroitin sulfate A, indicating its successful enzymatic hydrolysis.

[0074] Test Example 2

[0075] 15 mg of each of the chondroitin sulfate A oligosaccharide of Example 1, methacryloyl gelatin GelMA (L), GelMA (H) and chondroitin sulfate proteoglycan analog GMCS, and the chondroitin sulfate proteoglycan analog GMCS of Comparative Examples 1-2 were dissolved in 0.5 mL of D2O, and then loaded into a nuclear magnetic resonance tube and tested using a nuclear magnetic resonance spectrometer. The results are as follows: Figure 2-Figure 3 As shown. Figure 2-Figure 3It can be seen that GelMA (L) and GelMA (H) show peaks at 5.3ppm and 5.6ppm, which are the chemical shifts of the double bond of acrylamine. After integration, the double bond grafting rates of GelMA (L) and GelMA (H) are 34% and 74%, respectively. The GMCS peaks at 2.0ppm-2.5ppm show methyl hydrogen related to acetylamino, the peaks at 3.0ppm-4.0ppm show hydrogen related to sugar ring, and the peaks at 4.5ppm-5.5ppm show hydrogen related to carboxyl and sulfate groups, indicating that chondroitin sulfate A oligosaccharide is successfully modified to the protein core GelMA (L). With the increase of the feed ratio of chondroitin sulfate A oligosaccharide to GelMA in GMCS, the peak intensities at 2.0ppm-2.5ppm, 3.0ppm-4.0ppm and 4.5ppm-5.5ppm gradually increased, and the oligosaccharide grafting degree increased. When the feed ratio of chondroitin sulfate A oligosaccharide to GelMA (L) was 1:5, the oligosaccharide grafting degree of GMCS was the highest.

[0076] Test Example 3

[0077] 1 mg / mL of chondroitin sulfate A oligosaccharide, methacrylylated gelatin GelMA (L), and chondroitin sulfate proteoglycan analog GMCS in Example 1 were each taken and subjected to potential analysis using a Zeta potential analyzer. The results are shown in Table 1:

[0078] Table 1

[0079] Sample GelMA(L) Chondroitin sulfate A oligosaccharide GMCS Potential (mV) -4.566 -15.731 -9.820

[0080] As can be seen from Table 1, due to the covalent binding of chondroitin sulfate A oligosaccharide, the potential of GMCS is more electronegative than that of GelMA (L), which improves its binding ability to growth factors.

[0081] Test Example 4

[0082] 4 mg of each of the chondroitin sulfate A oligosaccharide, methacrylylated gelatin GelMA (L), and chondroitin sulfate proteoglycan analog GMCS of Example 1 were analyzed by combustion method. The results are as follows: Figure 1 As shown:

[0083] Table 2

[0084] Sample N[%] C[%] S[%] H[%] GelMA(L) 13.24 35.53 3.820 5.730 Chondroitin sulfate A oligosaccharide 25.69 47.20 0.721 5.399 GMCS 18.62 43.63 1.895 5.903

[0085] As can be seen from Table 2, the N, C, and S element contents of GMCS are closer to the average contents of the raw materials GelMA (L) and chondroitin sulfate A oligosaccharide, which proves the successful synthesis of chondroitin sulfate proteoglycan analogs.

[0086] Test Example 5

[0087] The contact angle test was performed on GelMA (L) of Example 1 and the chondroitin sulfate proteoglycan analog GMCS. The results are as follows: Figure 3 As shown. Figure 3 It can be seen that the contact angle of GelMA (L) in the left figure is 80.3°, and the contact angle of the chondroitin sulfate proteoglycan analog GMCS in the right figure is 66.3°, indicating that the introduction of a large number of hydroxyl groups on the chondroitin sulfate A sugar chain can form hydrogen bonds with water, thereby increasing the hydrophilicity of the protein core skeleton.

[0088] Test Example 6

[0089] Based on Example 1, the swelling of GelMA (H) microspheres and GMCS microspheres, a chondroitin sulfate proteoglycan analog, was compared by immersing them in PBS at 37°C. The results are as follows: Figure 5 As shown. Figure 5 It can be seen that both microspheres reached swelling equilibrium within 5 minutes, and the volume of the microspheres after swelling was between 100 μm and 200 μm. Among them, the volume of the chondroitin sulfate proteoglycan analog GMCS microspheres was larger, which verified that the introduction of hydroxyl groups on the CSA sugar chain could form hydrogen bonds with water, thereby improving the hydrophilicity of the protein core skeleton.

[0090] Test Example 7

[0091] 120 mg of the drug-containing chondroitin sulfate proteoglycan analog GMCS microspheres of Example 2 were tested for drug release in PBS (pH = 7.4) at 37°C and 100 rpm. 1 mL of samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 7, 8 and 9 days to detect the ultraviolet absorption at 238 nm, and 1 mL of PBS (pH = 7.4) was added at the same time to maintain the total volume unchanged. The results are as follows: Figure 6 As shown. Figure 6 It can be seen that the drug-containing chondroitin sulfate proteoglycan analog GMCS microspheres can release methylprednisolone in a sustained manner within 7 days.

[0092] Test Case 8

[0093] Based on Example 1, GelMA (H) microspheres and GMCS microspheres, and GMCS microspheres containing liposomes of Example 3 were swollen in water, and then freeze-dried in liquid nitrogen and subjected to gold spraying for scanning electron microscopy (SEM) analysis. The results are as follows: Figure 7 As shown. Figure 7It can be seen that the GelMA (H) microspheres in the upper figure have a smooth surface and small and dense pores; the diameter of the swelled GMCS microspheres in the middle figure is still around 200 μm. Due to the grafting of sugar chains, the pores of the microspheres become larger and the surface becomes rough; the lower figure shows that the liposomes are successfully encapsulated by the GMCS microspheres, and subsequently biological macromolecules such as proteins and nucleic acids can be encapsulated in the liposomes to improve their in vivo stability for targeted delivery into cells.

[0094] Test Example 9

[0095] The GMCS microspheres of Example 1 were incubated in the stem cell supernatant at 4°C for 24 hours to fully absorb the growth factors therein, and the supernatant on the surface was dried with filter paper and then rinsed twice with deionized water. The microspheres were then soaked in 1M NaCl at 4°C for 12 hours and then shaken for 1 hour for elution. The eluted growth factors were tested by SDS-PAGE. The results are as follows: Figure 8 As shown, 1 is Maker, 2 is stem cell supernatant containing growth factors, 3 is stem cell supernatant after soaking GMCS microspheres, 4 is deionized water after the first rinse, 5 is deionized water after the second rinse, and 6 is 1M NaCl after elution. Figure 8 It can be seen that the GMCS microspheres, a chondroitin sulfate proteoglycan analog, successfully adsorbed growth factors from the stem cell supernatant containing growth factors into their interior.

[0096] Test Example 10

[0097] 1 g of each of the GMCS microspheres of Example 1 and Comparative Examples 3-4 was placed on a strain-controlled rheometer at a constant temperature of 25° C. and a frequency sweep was performed in the shear rate range of 0.1 rad / s-100 rad / s. The results are shown in FIG. Fig. 9 As shown. Fig. 9 It can be seen that when the feed ratio of GMCS and GelMA in the composition of chondroitin sulfate proteoglycan analog GMCS microspheres is 2:5, the storage modulus (G') and loss modulus (G") of the hydrogel microspheres both reach the maximum, indicating that the chondroitin sulfate proteoglycan analog GMCS microspheres under this ratio prescription have the optimal viscoelasticity.

[0098] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.

Claims

1. A method for preparing chondroitin sulfate proteoglycan analog microspheres, characterized in that: The following steps are involved: S1, enzymatically hydrolyzing chondroitin sulfate with chondroitinase, and obtaining chondroitin sulfate oligosaccharides by ultrafiltration; S2, activating the chondroitin sulfate oligosaccharide described in S1 by a crosslinking agent, and then coupling it with the first methacrylylated gelatin, dialyzing and freeze-drying to obtain the chondroitin sulfate proteoglycan analog; the double bond grafting rate of the first methacrylylated gelatin is 30%-40%; S3, dissolving the chondroitin sulfate proteoglycan analogue described in S2, the second methacryloyl gelatin and the photoinitiator in water to obtain a dispersed phase; the double bond grafting rate of the second methacryloyl gelatin is 70%-80%; The oil phase material is the continuous phase; S4. The dispersed phase and the continuous phase described in S3 are made into water-in-oil droplets through a microfluidic device, and the chondroitin sulfate proteoglycan analog microspheres are obtained through UV curing and washing.

2. The method for preparing chondroitin sulfate proteoglycan analog microspheres according to claim 1, characterized in that: In S1, the chondroitinase is selected from chondroitin sulfate ABC enzyme or chondroitin sulfate AC enzyme; And / or, the chondroitin sulfate is selected from one or more of chondroitin sulfate A, chondroitin sulfate C and chondroitin sulfate E.

3. The method for preparing chondroitin sulfate proteoglycan analog microspheres according to claim 1, characterized in that: In S1, the enzymatic hydrolysis conditions are: temperature of 20°C-37°C, time of 20h-30h; And / or, during the enzymatic hydrolysis process, the concentration of chondroitinase is 0.2 mg / mL-0.5 mg / mL, and the concentration of chondroitin sulfate is 1 mg / mL-5 mg / mL.

4. The method for preparing chondroitin sulfate proteoglycan analog microspheres according to claim 1, characterized in that: In S2, the cross-linking agent includes EDC and NHS; the mass ratio of EDC to NHS is 1:(1-3); And / or, the mass ratio of the chondroitin sulfate oligosaccharide, the first methacryloyl gelatin and the cross-linking agent is (40-60):250:(6-11).

5. The method for preparing chondroitin sulfate proteoglycan analog microspheres according to claim 1, characterized in that: In S3, the photoinitiator is selected from photoinitiator LAP; And / or, the oil phase material is selected from one or more of Span 80, Span 60, paraffin oil, castor oil and soybean oil.

6. The method for preparing chondroitin sulfate proteoglycan analog microspheres according to claim 1, characterized in that: In S3, the mass ratio of the chondroitin sulfate proteoglycan analog to the second methacryloyl gelatin is 1:(2-4); the mass ratio of the second methacryloyl gelatin to the photoinitiator is (10-40):

1.

7. The method for preparing chondroitin sulfate proteoglycan analog microspheres according to claim 1, characterized in that: In S4, the specifications of the microfluidic device are: channel depth of 30 μm-60 μm, constriction width of 60 μm-120 μm, inner diameter of the pipeline of 0.3 mm-0.6 mm, and outer diameter of the pipeline of 1 mm-2 mm.

8. The method for preparing chondroitin sulfate proteoglycan analog microspheres according to claim 1, characterized in that: In S4, the process parameters of the microfluidic device are: the flow rate of the dispersed phase is 0.3 mL / h-0.8 mL / h, and the flow rate of the continuous phase is 5 mL / h-10 mL / h.

9. The method for preparing chondroitin sulfate proteoglycan analog microspheres according to claim 1, characterized in that: In S4, the UV curing conditions are: wavelength of 365nm-405nm, irradiation power of 50mW·cm -2 -200mW·cm -2 , irradiation time is 30s-180s; And / or, the washing is firstly with petroleum ether and then with water.

10. A chondroitin sulfate proteoglycan analog microsphere prepared by the method according to any one of claims 1 to 9, characterized in that: The diameter of the chondroitin sulfate proteoglycan analog microspheres is 50 μm-200 μm.

Citation Information

Patent Citations

  • Hydrogel microspheres for repairing bone defects and preparation method thereof

    CN113181434A

  • Hydrogel composition, hydrogel, bionic cartilage and preparation method and application thereof

    CN113440651A

  • Photocuring molding composite hydrogel matrix precursor, preparation method thereof and stent with photocuring molding composite hydrogel matrix precursor

    CN113679888A

  • Porous hydrogel microsphere and preparation method thereof

    CN113801367A

  • Biological ink for spatial tissue and organ model construction, suspension medium and suspension 3D printing method

    CN117618664A

Cited By

  • Microsphere based on methacrylated gelatin, preparation method of microsphere and application of microsphere in bio-ink

    CN121588283A